riskScore® Validation March 25, 2021 The recent publication in JCO Precision Oncology demonstrates the value of a combined risk score that incorporates polygenic risk and clinical variables for pre... Continue Reading
CHEK2 riskScore Clinical Scenario – High Risk October 1, 2020 A 46-year-old woman without a personal history of cancer presents to her provider to better understand her risk of breast cancer. Her sister was diagnosed with ... Continue Reading
CHEK2 riskScore Clinical Scenario – Low Risk September 23, 2020 A 41-year-old woman without a personal history of cancer presents to her provider to better understand her risk of breast cancer. Her mother, maternal grandmoth... Continue Reading
CHEK2 riskScore Clinical Scenario – Moderate Risk September 17, 2020 A healthy 37-year-old woman approaches her doctor because she is concerned about her risk of breast cancer. Her mother, maternal aunt, and maternal grandmother ... Continue Reading
Cost of Myriad myRisk Testing August 10, 2020 Cost should never be a barrier when patients need genetic testing. That’s why it’s Myriad’s promise to make testing accessible and affordable. For pati... Continue Reading
Variant Reclassification July 20, 2020 Why is Variant Reclassification in Hereditary Cancer Testing Important? Variant classification is a key component of germline testing, allowing patients to ... Continue Reading
CHEK2 Carrier Modification with Polygenic Risk Score July 7, 2020 High and moderate penetrant genes, such as BRCA1, BRCA2, PALB2, CHEK2, and ATM, account for approximately 25% of familial breast cancer risk. 1-4 An additional ... Continue Reading
Myriad Oncology Live – Weekly Educational Webinar Series July 1, 2020 In my new role as Senior Vice President of Medical Affairs of Myriad Oncology, I want to be completely accessible to our providers. Because of COVID-19, Myriad ... Continue Reading
An Overview of riskScore June 9, 2020 Myriad’s myRisk Hereditary Cancer test includes analysis of several well-known breast cancer genes. However, 10% or fewer of breast cancers in women are hered... Continue Reading
Myriad Corporate Statement June 9, 2020 We are heartbroken over the systemic discrimination and racism that have persisted in this nation for too long. We have been quiet in reflection but believe tha... Continue Reading
Introducing the Inside the GENOME Podcast June 4, 2020 Hosted by Dr. Thomas Slavin, Senior Vice President of Medical Affairs for Myriad Oncology, Inside the GENOME is a casual, educational podcast exploring the worl... Continue Reading
Notes from the Field: Cancer Genetics Counseling During a Pandemic May 13, 2020 Cancer patients face a mountain of stress. As they are hearing unwelcome, life-changing news, they must also understand detailed medical information to make ti... Continue Reading
Listen to Dr. Slavin Outline Myriad Oncology’s Digital Tools March 24, 2020 We understand that in the current climate, there may be difficulties in delivering care to your patients due certain restrictions in travel and the ability to... Continue Reading
A Message From Myriad About COVID-19 March 16, 2020 In light of the public health preparedness efforts currently underway, Myriad’s top priorities are protecting the health and safety of employees, our customer... Continue Reading
Welcome Providers March 4, 2020 Welcome to the new Myriad Oncology website! For over 25 years, we have been dedicated to giving healthcare providers and patients answers they can trust. From h... Continue Reading